Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles

Histopathology

Volumn 55, Issue 5, 2009, Pages 594-599

  Lopes, Nair ^a   Sousa, Bárbara ^a   Vieira, Daniella ^b   Milanezi, Fernanda ^a,c   Schmitt, Fernando ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF MINHO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Basal like; Breast cancer; Endoglin; Vascularity

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER THERAPY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANTIGENS, CD; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 71049118533     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03417.x     Document Type: Article

References (23)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007 18 581 592. (Pubitemid 46359643)
2. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005 447 688 694.
3. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001 98 10869 10874.
4. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
5. Oh DS, Troester MA, Usary J et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol. 2006 24 1656 1664.
6. Paredes J, Lopes N, Milanezi F, Schmitt FC. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. 2007 450 73 80.
7. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004 10 5367 5374.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 57 70.
9. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv. Cancer Res. 1996 69 135 174.
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 86 353 364.
11. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur. J. Cancer 1996 32A 2451 2460.
12. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2001 2 278 289.
13. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J. Clin. Oncol. 2005 23 3243 3256.
14. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracilleucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 2005 23 3706 3712.
15. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 2001 280 C1358 C1366.
16. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004 3 391 400.
17. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006 3 24 40.
18. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol. Int. 2006 56 717 723.
19. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J. Natl Cancer Inst. 2000 92 1388 1402.
20. Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc. Res. Tech. 2001 52 437 449. (Pubitemid 32167832)
21. Marinho A, Soares R, Ferro J, Lacerda M, Schmitt FC. Angiogenesis in breast cancer is related to age but not to other prognostic parameters. Pathol. Res. Pract. 1997 193 267 273.
22. Dales JP, Garcia S, Bonnier P et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am. J. Clin. Pathol. 2003 119 374 380. (Pubitemid 37047860)
23. Lee SH, Mizutani N, Mizutani M et al. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol. Immunother. 2006 55 1565 1574.